David Donnersberger, MD
Internal Medicine · Winnetka, ILNPI 1003927948
Payments from drug & device makers
Across 87 payments — averaging $20.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$315
- Amgen$254
- Lilly USA, LLC$131
- AbbVie$125
- Bayer$122
- AstraZeneca$98
- plus $742 from 20 others
What the payments were for
- Food & beverage$1,75298%
- Education$352%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 12 | $315 |
| Amgen | 12 | $254 |
| Lilly USA, LLC | 7 | $131 |
| AbbVie(2 entities) | 7 | $125 |
| Bayer | 6 | $122 |
| AstraZeneca | 5 | $98 |
| Sanofi Pasteur Inc. | 4 | $86 |
| Exact Sciences | 4 | $82 |
| GSK | 3 | $69 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $46 |
| Johnson & Johnson | 2 | $42 |
| Novo Nordisk | 2 | $40 |
| Merck | 2 | $39 |
| Astellas Pharma US Inc | 2 | $39 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $36 |
| VBI Vaccine (delaware) Inc. | 2 | $35 |
| Hikma Pharmaceuticals USA | 2 | $35 |
| Inspire Medical Systems, Inc. | 1 | $26 |
| Medtronic | 1 | $25 |
| Bausch Health US, LLC | 1 | $23 |
| Genentech USA, Inc. | 1 | $23 |
| Boehringer Ingelheim | 1 | $23 |
| E.r. Squibb & Sons, L.L.C. | 1 | $21 |
| Sunovion Pharmaceuticals Inc. | 2 | $20 |
| Novartis | 1 | $19 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
How this compares
$1,787 in reported general payments places this provider in the 80th percentile of 5,182 internal medicine providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 135 | $162,789 |
| XareltoRivaroxaban | 79 | $80,836 |
| RybelsusSemaglutide | 13 | $32,154 |
| MyrbetriqMirabegron | 39 | $30,674 |
| OzempicSemaglutide | 27 | $30,201 |
| JardianceEmpagliflozin | 17 | $28,879 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 38 | $25,128 |
| FarxigaDapagliflozin Propanediol | 26 | $25,069 |
| LinzessLinaclotide | 16 | $23,605 |
| JanuviaSitagliptin Phosphate | 13 | $10,871 |
| SynthroidLevothyroxine Sodium | 89 | $9,172 |
| KristaloseLactulose | 11 | $8,581 |
| LivaloPitavastatin Calcium | 14 | $7,464 |
| Atorvastatin Calcium | 388 | $5,233 |
| Levothyroxine Sodium | 283 | $5,041 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $315 | $162,789135 claims |
| Johnson & JohnsonXarelto | $42 | $80,83679 claims |
| Novo NordiskRybelsus, Ozempic | $40 | $62,35540 claims |
| AbbVieLinzess, Synthroid | $125 | $32,777105 claims |
| Astellas Pharma US IncMyrbetriq | $39 | $30,67439 claims |
| Boehringer IngelheimJardiance | $23 | $28,87917 claims |
| GSKTrelegy Ellipta | $69 | $25,12838 claims |
| AstraZenecaFarxiga | $98 | $25,06926 claims |
| MerckJanuvia | $39 | $10,87113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 5,182 internal medicine providers in Illinois.
Other internal medicine in Winnetka
- Kristi Tough DesapriWinnetka$345K
- Dennis LevinsonChicago$25.3M
- Mary BrownRockford$16M
- Andrew BartlettChampaign$4.1M
- Danny SugimotoChicago$4M
- Peter O DonnellChicago$3.9M
- Daniel CatenacciChicago$3.5M
- Jeffrey GeohasEvanston$2.3M
- Patricia WalshChicago$2.1M
- Merle DiamondChicago$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.